Ruxolitinib Plus Nivolumab in Patients With R/R Hodgkin Lymphoma After Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Bachanova V

• Presentation # 230 – Oral*
  December 11, 2021 | 02:15 PM EST

• Abstract

A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data From the REVEAL Study)

Gerds AT

• Presentation # 239 – Oral*
  December 11, 2021 | 03:00 PM EST

• Abstract

A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Cell Transplantation for Patients With Primary or Secondary Myelofibrosis

Hobbs G

• Presentation # 169 – Oral*
  December 11, 2021 | 12:00 PM EST

• Abstract

Validation of Amphiregulin as a Monitoring Biomarker During Treatment of Life-Threatening Acute GVHD: A Secondary Analysis of 2 Prospective Clinical Trials

Pratta M

• Presentation # 259 – Oral*
  December 11, 2021 | 02:00 PM EST

• Abstract

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients With Relapsed or Refractory Multiple Myeloma

Berenson JR

• Presentation # 2727 – Poster*
  December 12, 2021 | 06:00 PM EST

• Abstract

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Borate U

• Presentation # 2333 – Poster*
  December 12, 2021 | 06:00 PM EST

• Abstract

Disability Associated With Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Hamilton BK

• Presentation # 4060 – Poster*
  December 13, 2021 | 06:00 PM EST

• Abstract

Characteristics of High-Risk Polycythemia Vera Patients With Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings From PV-SWITCH, a Multinational, Retrospective Chart Review Study

Koschmieder S

• Presentation # 3646 – Poster
  December 13, 2021 | 06:00 PM EST

• Abstract
  
  
  

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Lee SJ

• Presentation # 3909 – Poster
  December 13, 2021 | 06:00 PM EST

• Abstract
  
  
  
  
  

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data From the MOST Study)

Lyons R

• Presentation # 1497 – Poster*
  December 11, 2021 | 05:30 PM EST

• Abstract

ADORE: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients With Myelofibrosis

Ross DM

• Presentation # 1489 – Poster
  December 11, 2021 | 05:30 PM EST

• Abstract
  
  
  

Second Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Sweet K

• Presentation # 2555 – Poster*
  December 12, 2021 | 06:00 PM EST

• Abstract

Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies

Verstovsek S

• Presentation # 1505 – Poster*
  December 11, 2021 | 05:30 PM EST

• Abstract

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Add-On Parsaclisib in Patients With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Yacoub A

• Presentation # 1502 – Poster*
  December 11, 2021 | 05:30 PM EST

• Abstract

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients With JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis

Yacoub A

• Presentation # 2579 – Poster*
  December 12, 2021 | 06:00 PM EST

• Abstract

Subgroup Analysis From a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients With Myelofibrosis (MF)

Yacoub A

• Presentation # 3647 – Poster*
  December 13, 2021 | 06:00 PM EST

• Abstract